Capital, LLC EcoR1, a director at $ZYME, bought 31,033 shares of the company on 03-21-2025 for an estimated $396,517. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their holdings of this class of stock by approximately 0.2%. Following this trade, they now own 17,135,113 shares of this class of $ZYME stock.
$ZYME Insider Trading Activity
$ZYME insiders have traded $ZYME stock on the open market 27 times in the past 6 months. Of those trades, 22 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $ZYME stock by insiders over the last 6 months:
- CAPITAL, LLC ECOR1 has made 22 purchases buying 2,465,521 shares for an estimated $32,051,174 and 0 sales.
- KENNETH GALBRAITH (Chair & CEO) has made 0 purchases and 2 sales selling 57,291 shares for an estimated $855,016.
- PAUL ANDREW MOORE (Chief Scientific Officer) has made 0 purchases and 2 sales selling 21,200 shares for an estimated $316,390.
- JEFFREY T L SMITH (EVP & Chief Medical Officer) sold 11,110 shares for an estimated $165,806
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ZYME Hedge Fund Activity
We have seen 70 institutional investors add shares of $ZYME stock to their portfolio, and 98 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ECOR1 CAPITAL, LLC added 1,590,606 shares (+11.8%) to their portfolio in Q4 2024, for an estimated $23,286,471
- MORGAN STANLEY removed 905,432 shares (-17.7%) from their portfolio in Q4 2024, for an estimated $13,255,524
- BLACKSTONE INC. added 544,633 shares (+2171.4%) to their portfolio in Q4 2024, for an estimated $7,973,427
- SIO CAPITAL MANAGEMENT, LLC removed 491,128 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $6,163,656
- WALLEYE CAPITAL LLC added 452,804 shares (+inf%) to their portfolio in Q4 2024, for an estimated $6,629,050
- VESTAL POINT CAPITAL, LP removed 430,000 shares (-69.9%) from their portfolio in Q4 2024, for an estimated $6,295,200
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 407,771 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $5,969,767
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ZYME Analyst Ratings
Wall Street analysts have issued reports on $ZYME in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 03/07/2025
- Leerink Partners issued a "Outperform" rating on 11/21/2024
- H.C. Wainwright issued a "Buy" rating on 10/22/2024
To track analyst ratings and price targets for $ZYME, check out Quiver Quantitative's $ZYME forecast page.
$ZYME Price Targets
Multiple analysts have issued price targets for $ZYME recently. We have seen 3 analysts offer price targets for $ZYME in the last 6 months, with a median target of $26.0.
Here are some recent targets:
- Andrew Berens from Leerink Partners set a target price of $26.0 on 11/21/2024
- Derek Archila from Wells Fargo set a target price of $12.0 on 11/01/2024
- Stephen Willey from Stifel Nicolaus set a target price of $28.0 on 10/28/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
